Gutiérrez A, Ariza R, Frati-Munari A C, Oliva G, Mas-Oliva J
Departamento de Medicina Interna, Hospital de Especialidades, Centro Médico La Raza, IMSS, México, D.F.
Arch Invest Med (Mex). 1991 Jul-Dec;22(3-4):279-83.
The erythrocyte (Ca2+,Mg2+)-ATPase activity from 12 hypertensive and 14 normotensive subjects have been compared. No differences were found in the calcium-ATPase activity from both studied groups. When the calcium-ATPase assay was carried out in the presence of EGTA, we observed a partial stimulatory effect of the activity, but a blunted stimulation by calmodulin in both membrane preparations. When the EGTA was removed and a total concentration of calcium (100 uM) was kept constant in the incubation media, calmodulin stimulated the ATPase four fold over the non stimulated conditions in both studied groups. It is concluded that the use of EGTA buffers in the assay of the calcium-ATPase in the erythrocyte membrane of normotensive and hypertensive patients, must be used with caution, since a different enzyme sensitive to EGTA in the normotensive and the hypertensive membranes could give an erroneous interpretation of the results. This condition could partially explain the controversies in recent reports investigating the (Ca2+,Mg2+)-ATPase activity and calcium transport in different cell systems isolated from hypertensive patients.
对12名高血压患者和14名血压正常者的红细胞(Ca2 +,Mg2 +)-ATP酶活性进行了比较。研究的两组之间的钙ATP酶活性未发现差异。当在EGTA存在的情况下进行钙ATP酶测定时,我们观察到该活性有部分刺激作用,但在两种膜制剂中钙调蛋白的刺激作用均减弱。当去除EGTA并使孵育介质中的钙总浓度(100μM)保持恒定时,在两个研究组中,钙调蛋白刺激ATP酶的作用比未刺激条件下增强了四倍。得出的结论是,在测定血压正常者和高血压患者红细胞膜中的钙ATP酶时,使用EGTA缓冲液必须谨慎,因为血压正常者和高血压患者的膜中对EGTA敏感的不同酶可能会对结果产生错误的解释。这种情况可以部分解释最近关于从高血压患者分离的不同细胞系统中(Ca2 +,Mg2 +)-ATP酶活性和钙转运的研究报告中的争议。